Comparative Pharmacology
Head-to-head clinical analysis: ANORO ELLIPTA versus ICOTYDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANORO ELLIPTA versus ICOTYDE.
ANORO ELLIPTA vs ICOTYDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ANORO ELLIPTA is a combination of umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta2-adrenergic agonist (LABA). Umeclidinium inhibits acetylcholine at M3 receptors in bronchial smooth muscle, causing bronchodilation. Vilanterol stimulates beta2-adrenergic receptors, leading to relaxation of bronchial smooth muscle and increased cyclic AMP.
ICOTYDE (trifluridine/tipiracil) is a combination of trifluridine, a thymidine-based nucleoside analog that incorporates into DNA and inhibits cell proliferation, and tipiracil, a thymidine phosphorylase inhibitor that increases the systemic exposure of trifluridine by inhibiting its degradation.
One inhalation (umeclidinium 62.5 mcg / vilanterol 25 mcg) once daily, orally inhaled.
Intravenous: 1000 mg administered over 90 minutes on days 1 and 15 of a 28-day cycle.
None Documented
None Documented
Umeclidinium: 11 hours (terminal); vilanterol: 2.5 hours (terminal). Steady-state achieved by day 14 once-daily dosing.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; may be prolonged in renal impairment.
Umeclidinium: 0.7% unchanged in urine, 58% as metabolites in feces; vilanterol: 26% unchanged in urine, 70% as metabolites in feces. Total elimination: renal (30-40% for vilanterol metabolites) and fecal (primary).
Renal excretion of unchanged drug accounts for approximately 70% of elimination, with biliary/fecal elimination contributing the remaining 30%.
Category C
Category C
LAMA/LABA Combination
ICS/LABA Combination